BRUIN: Durable benefits with pirtobrutinib in patients with R/R Waldenström macroglobulinemia

Lymphoma

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

EHA 2025

Leukemia

ZUMA-3: Long-term survival benefit with brexu-cel in patients with R/R B-ALL

ASH 2025

Lymphoma

ROSEWOOD: Sustained benefits with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in heavily pretreated patients with R/R FL

ASH 2025

BRUIN CLL-314: Pirtobrutinib demonstrates noninferior ORR versus ibrutinib in the first head-to-head trial in BTKi-naïve patients with CLL/SLL

ASH 2025

Lymphoma

TRANSCEND FL: High rates of deep and durable responses and sustained survival with liso-cel in patients with R/R FL after three years of follow-up

EHA 2025

Lymphoma

Real-world effectiveness and safety of second-line axi-cel in patients with R/R LBCL

ASH 2025

Leukemia

LBA-3: BRUIN CLL-313: Pirtobrutinib is superior to bendamustine plus rituximab in treatment-naïve CLL/SLL

Lung, Respiratory and Thoracic Cancer

Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile study

Transl Lung Cancer Res

Auclin E, Du Rusquec P, Albarran-Artahona V, Aboubakar F, Gerber H, Epaillard N, Recondo G, De Giglio A, Berthou H, Laguna JC, Gorria T, Blaquier JB, Jimenez-Munarriz B, Tagliamento M, Di Federico A, Sacco G, Minatta J, Girard N, Moran-Bueno T, Lopez-Castro R, Besse B, Mezquita L

doi: 10.21037/tlcr-24-881

ASH 2025

Leukemia

Related content

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

ZUMA-3: Long-term survival benefit with brexu-cel in patients with R/R B-ALL

ROSEWOOD: Sustained benefits with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in heavily pretreated patients with R/R FL

BRUIN CLL-314: Pirtobrutinib demonstrates noninferior ORR versus ibrutinib in the first head-to-head trial in BTKi-naïve patients with CLL/SLL

TRANSCEND FL: High rates of deep and durable responses and sustained survival with liso-cel in patients with R/R FL after three years of follow-up

Real-world effectiveness and safety of second-line axi-cel in patients with R/R LBCL

LBA-3: BRUIN CLL-313: Pirtobrutinib is superior to bendamustine plus rituximab in treatment-naïve CLL/SLL

Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile study

ADMIRAL/COMMODORE: A lower risk of relapse or death with gilteritinib maintenance post-HSCT in patients with R/R FLT3mut AML

ADMIRAL/COMMODORE: A lower risk of relapse or death with gilteritinib maintenance post-HSCT in patients with R/R FLT3^mut AML